Allspring Global Investments Holdings LLC Purchases 288,148 Shares of Cencora, Inc. $COR

Allspring Global Investments Holdings LLC grew its position in Cencora, Inc. (NYSE:COR) by 212.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 423,706 shares of the company’s stock after purchasing an additional 288,148 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Cencora were worth $132,099,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Security Financial Services INC. increased its position in shares of Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after acquiring an additional 33 shares during the last quarter. Atlantic Edge Private Wealth Management LLC increased its position in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Grove Bank & Trust raised its stake in shares of Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after purchasing an additional 36 shares during the period. Quadcap Wealth Management LLC boosted its holdings in shares of Cencora by 1.5% in the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after buying an additional 36 shares during the last quarter. Finally, U.S. Capital Wealth Advisors LLC grew its position in Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock valued at $2,563,000 after buying an additional 38 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 20,317 shares of company stock worth $7,009,260. 10.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on COR shares. TD Cowen boosted their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Robert W. Baird set a $392.00 price objective on Cencora in a research note on Tuesday, December 16th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a research report on Monday. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, UBS Group increased their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average price target of $373.25.

Cencora Trading Down 0.1%

Shares of COR opened at $340.03 on Wednesday. Cencora, Inc. has a twelve month low of $223.92 and a twelve month high of $377.54. The stock has a market cap of $65.96 billion, a PE ratio of 42.77, a P/E/G ratio of 1.62 and a beta of 0.63. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The business’s 50-day moving average price is $349.14 and its 200-day moving average price is $315.91.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the business posted $3.34 earnings per share. Cencora’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.